Key Viral Hepatitis Studies From AASLD 2021

November 12-15, 2021; Virtual
Read expert faculty members’ summaries of HBV, HCV, and hepatitis delta virus (HDV), including data on HBV therapy during pregnancy, outcomes following treatment withdrawal in HBV, progress toward an HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and current status of the cascade of care.
Nancy Reau, MD
Stefan Zeuzem, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 323 KB
Released: November 29, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Expert analysis by Dr Nancy Reau on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 8, 2022

Clinical Care Options (CCO) expert analysis by Dr Stefan Zeuzem on new viral hepatitis data from AASLD 2022

Stefan Zeuzem, MD Released: December 8, 2022

Dr Nancy Reau: practice-changing viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 6, 2022

Clinical Care Options (CCO) podcast with Dr Stefan Zeuzem on key viral hepatitis data from AASLD 2022

Stefan Zeuzem, MD Released: December 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings